Latest filing published 20 Jun 2024 for Pacific Biosciences of California, INC..
Filing timeline
BuySaleFirst 200 filings with a declared amount
Insider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -57.5%Entry US$47.36 · Close at T+365 US$20.14
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
John F. Milligan: trading record in brief
Filings by John F. Milligan span 3 companies, the busiest being Gilead Sciences, Inc., Pacific Biosciences of California, Inc. and 4D Molecular Therapeutics, Inc. In total, 308 filings cover trades dated from 6 February 2006 to 18 June 2024.
In open-market terms, that means 1 purchase worth €1.9M on one side and 197 sales worth €312.3M on the other. The net balance comes to €310.4M on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 36 share grants and 73 option exercises.
The record was last updated on 20 June 2024 with a share grant in Pacific Biosciences of California, Inc. The latest purchase dates back some time: it was published 2,152 days ago, on 17 December 2020. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to John F. Milligan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 22,821 shares0Common StockSEC:0001299130-24-000152:0
- 100,000 shares@ US$23.00100.0% of flowCommon StockSEC:0001567619-20-021289:0Canonical exit: 15 Mar 2021 (T+90)
- 35,000 shares@ US$2.6725.6% of flowCommon StockSEC:0001209191-20-048447:0
- 25,000 shares@ US$4.4530.5% of flowCommon StockSEC:0001209191-20-048447:1
- 25,000 shares@ US$3.8126.1% of flowCommon StockSEC:0001209191-20-048447:2
- 25,000 shares@ US$2.6117.9% of flowCommon StockSEC:0001209191-20-048447:3
- 280,000 shares@ US$23.6071.3% of flowCommon StockSEC:0001127602-18-034776:0
- 80,000 shares@ US$27.071.9% of flowCommon StockSEC:0001127602-18-016673:0
- 48,342 shares0Common StockSEC:0001127602-18-008143:1
- 7,709 shares0Common StockSEC:0001127602-18-008143:2
- 340 shares@ US$62.350.0% of flowCommon StockSEC:0001127602-18-008143:0
- 8,009 shares@ US$80.690.5% of flowCommon StockSEC:0001127602-18-008143:3
- 220,000 shares@ US$21.584.2% of flowCommon StockSEC:0001127602-17-032178:0
- 220,000 shares@ US$72.8814.3% of flowCommon StockSEC:0001127602-17-032178:1
- 100,000 shares@ US$21.582.1% of flowCommon StockSEC:0001127602-17-008707:0
- 315 shares@ US$59.330.0% of flowCommon StockSEC:0001127602-17-007564:0
- 8,389 shares@ US$70.310.6% of flowCommon StockSEC:0001127602-17-007564:3
- 11,606 shares0Common StockSEC:0001127602-17-007564:1
- 3,429 shares0Common StockSEC:0001127602-17-007564:2
- 70,000 shares@ US$20.741.3% of flowCommon StockSEC:0001127602-16-062200:0
- 70,000 shares@ US$77.745.0% of flowCommon StockSEC:0001127602-16-062200:1
- 70,000 shares@ US$20.741.3% of flowCommon StockSEC:0001127602-16-059418:0
- 70,000 shares@ US$70.944.6% of flowCommon StockSEC:0001127602-16-059418:1
- 112,000 shares@ US$16.401.7% of flowCommon StockSEC:0001127602-16-057737:0
- 103,370 shares@ US$84.288.2% of flowCommon StockSEC:0001127602-16-057737:1
25 of 304 declarations
